drugset / Trial / NCT02591199
Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine if the combination product (URG101) is safe and effective versus its individual components (Heparin Sodium and Lidocaine Hydrochloride) for the treatment of Interstitial Cystitis/Bladder Pain Syndrome. The study is randomized and double-blinded such that neither the subject nor doctor will know which drug or placebo is received.
Timeline
- Start
- 2015-09
- Primary completion
- 2018-05-14
- Completion
- 2018-06-18
Outcome
Outcome not reported
Stopped (Business): “Prematurely terminated due to data inconsistent with the experimental plan and lack of funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Heparin | Other / unclassified | 50000 iu | Other |
| Subject | Lidocaine | Other / unclassified | 200 mg | Other |
| Subject | URG101 | Unknown | 15 ml | Other |